Induction Therapies for Locally Advanced Marginally Resectable and Unresectable Escc and Conversion Surgery Prognosis: A Real-World Study

View Full Paper

Ask AI

Bookmark

Induction therapy significantly improves conversion surgery outcomes for borderline resectable tumors.
The objective response rate of primary tumors post-induction was 49.7%, with notable lymph node response rates.
Immunochemotherapy showed superior efficacy compared to chemotherapy and chemoradiotherapy in lymph node response.
Patients undergoing conversion surgery exhibited better overall survival than those receiving non-surgical treatment.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective study examines conversion surgery benefits for BR-ESCC and UR-ESCC, suggesting induction therapy impacts prognosis.

Zhang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark